FRAMINGHAM, Mass., Dec. 17, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, California based genomics tools manufacturer, today announced Framingham, Massachusetts based Eurofins Clinical ...

Complete Genomics and Velsera are collaborating to deliver an end-to-end genetic testing solution that integrates DNBSEQ™ sequencing technology with Velsera’s Clinical Genomics Workspace (CGW) data ...

Complete Genomics will share details of various multi-omics and spatial transcriptomics applications based on its sequencing technology at the 2024 American Society of Human Genetics (ASHG) Meeting.

BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (SOPH) (Nasdaq: SOPH), a global leader in ...

BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing technologies, will showcase its expanded portfolio for oncology and infectious disease research at ...

SAN JOSE, Calif., May 23, 2024 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, recently welcomed vendors, suppliers, customers and employees to a May 17 grand opening ...

BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (SOPH) (NASDAQ: SOPH), a global leader in ...

The DNBSEQ-T1+ is a next-generation mid-throughput sequencer that completes a paired end 150 sequencing workflow in just 24 hours with Q40 accuracy. With three flow cell formats, two to four ...

SAN JOSE, Calif., April 15, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced four winners from 30 applicants to its Spatial Xcellerator Grant Program.

BOSTON, Oct. 14, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a series of milestones at the American Society of Human Genetics (ASHG) Annual ...

With confidence dropping in doing business with China-affiliated life sciences companies due to the Biosecure Act, one of the companies explicitly named in the U.S. legislation is fighting back.